Pacific Shuanglin Bio-pharmacy Co., LTD

SZSE:000403 Stock Report

Market Cap: CN¥15.6b

Pacific Shuanglin Bio-pharmacy Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Xiankui Rong

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.2yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure1.2yrs

Recent management updates

Recent updates

Benign Growth For Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) Underpins Its Share Price

Nov 25
Benign Growth For Pacific Shuanglin Bio-pharmacy Co., LTD (SZSE:000403) Underpins Its Share Price

If EPS Growth Is Important To You, Pacific Shuanglin Bio-pharmacy (SZSE:000403) Presents An Opportunity

Oct 10
If EPS Growth Is Important To You, Pacific Shuanglin Bio-pharmacy (SZSE:000403) Presents An Opportunity

Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Shares May Have Run Too Fast Too Soon

Aug 16
Pacific Shuanglin Bio-pharmacy Co., LTD's (SZSE:000403) Shares May Have Run Too Fast Too Soon

We Think Pacific Shuanglin Bio-pharmacy (SZSE:000403) Can Stay On Top Of Its Debt

Jul 22
We Think Pacific Shuanglin Bio-pharmacy (SZSE:000403) Can Stay On Top Of Its Debt

Is Now The Time To Put Pacific Shuanglin Bio-pharmacy (SZSE:000403) On Your Watchlist?

May 24
Is Now The Time To Put Pacific Shuanglin Bio-pharmacy (SZSE:000403) On Your Watchlist?

CEO

Xiankui Rong (50 yo)

1.2yrs

Tenure


Leadership Team

NamePositionTenureCompensationOwnership
Yehong Wang
CFO & Accounting Supervisor3.8yrsCN¥1.57m0.012%
CN¥ 1.8m
Lei Yan
Deputy GM & Directorless than a yearCN¥1.61mno data
Wenbin Si
Deputy GM & Non-Independent Directorless than a yearCN¥101.00k0.000030%
CN¥ 4.7k
Xiaoying Huang
Deputy GM & Non-Independent Directorless than a yearCN¥101.00kno data
Lan Ye
Deputy GM & Non-Independent Directorless than a yearCN¥101.00kno data
Yulin Zhao
Board Secretary5.6yrsCN¥1.88m0.022%
CN¥ 3.5m
Xiankui Rong
General Manager1.2yrsno datano data

1.0yrs

Average Tenure

43yo

Average Age

Experienced Management: 000403's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Lei Yan
Deputy GM & Directorless than a yearCN¥1.61mno data
Wenbin Si
Deputy GM & Non-Independent Director1.2yrsCN¥101.00k0.000030%
CN¥ 4.7k
Xiaoying Huang
Deputy GM & Non-Independent Director1.2yrsCN¥101.00kno data
Lan Ye
Deputy GM & Non-Independent Director1.2yrsCN¥101.00kno data
Shaolan Fu
Co-Chairman3.8yrsCN¥3.05mno data
Li Yang
Directorless than a yearCN¥1.92m1.08%
CN¥ 169.0m
Zuojun Dong
Independent Director3.8yrsCN¥100.00kno data
Hao Li
Chairman1.2yrsno datano data
Jun Yin
Independent Director1.2yrsCN¥18.60kno data
Wenqi Wang
Independent Director1.2yrsCN¥18.60kno data
Hui Guo
Chairman of the Supervisory Board1.2yrsno datano data
Jun Liu
Independent Directorless than a yearCN¥6.00kno data

1.2yrs

Average Tenure

51yo

Average Age

Experienced Board: 000403's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 14:44
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pacific Shuanglin Bio-pharmacy Co., LTD is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Feifei XuChina Merchants Securities Co. Ltd.
Zhu ChenCitic Securities Co., Ltd.
Kai WangCitic Securities Co., Ltd.